Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man
| Autor: | Claire Troakes, F. House, H. S. Somal, J. L. Palmer, R. J. Wright, J. R. R. Stott, Stacy A. Clemes, K. Reid |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male Adolescent Motion Sickness Nausea medicine.drug_class Scopolamine Tetrazoles Ondansetron 5-HT3 Receptor Antagonist Short Reports Double-Blind Method Neurokinin-1 Receptor Antagonists Piperidines 5-HT3 antagonist medicine Humans Antiemetic Pharmacology (medical) Pharmacology Cross-Over Studies business.industry Antagonist Middle Aged Receptor antagonist Anesthesia Antiemetics Drug Therapy Combination Female NK1 receptor antagonist Serotonin Antagonists medicine.symptom business medicine.drug |
| Zdroj: | British Journal of Clinical Pharmacology. 50:61-64 |
| ISSN: | 0306-5251 |
| Popis: | Aims In man a neurokinin-1 (NK1) receptor antagonist has previously been shown to be ineffective in the prevention of motion-induced nausea. The antiemetic efficacy of NK1 receptor antagonists against chemotherapy-induced emesis is, however, enhanced when combined with a 5-HT3 receptor antagonist. Hence the efficacy of the NK1 antagonist GR205171 in combination with the 5-HT3 antagonist ondansetron (Zofran™) was assessed in motion-induced nausea. Methods GR205171 25 mg i.v., with and without concomitant administration of ondansetron 8 mg i.v., and hyoscine hydrobromide 0.6 mg orally (positive control) were compared with placebo in a model of motion-induced nausea. The study was performed to a four-period, randomized, balanced, double-blind, crossover design in 16 healthy subjects. The end-point was the exposure to the motion stimulus required to produce moderate nausea in the subjects. Results The motion stimulus required to produce moderate nausea was significantly greater for the positive control than placebo (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text